Lilly reports Taltz Zepbound trial results

• Eli Lilly reported Phase 3b results showing Taltz plus Zepbound improved combined disease control and weight loss outcomes.
• The combination achieved higher rates of complete skin clearance and psoriatic arthritis responses compared with Taltz alone.
• Lilly said improvements in inflammation and metabolic measures continued through 52 weeks with no new safety concerns.

Eli Lilly (NYSE:LLY) reported 52-week results from the Phase 3b TOGETHER-PsO and TOGETHER-PsA trials showing Taltz (ixekizumab) plus Zepbound (tirzepatide) improved outcomes compared with Taltz alone in adults with psoriasis or psoriatic arthritis and overweight or obesity.

The trials evaluated whether combining an immune-targeting therapy with a weight-management treatment could improve disease outcomes and weight reduction compared with treatment using Taltz alone.

In TOGETHER-PsO, 30.6% of patients receiving Taltz plus Zepbound achieved PASI 100 and at least 10% weight loss compared with 4.4% receiving Taltz alone, while TOGETHER-PsA showed ACR50 and at least 10% weight loss in 39.2% versus 1.7%.

Lilly reported complete skin clearance in psoriasis of 40.5% with combination therapy compared with 29.1% with Taltz alone and ACR50 responses in psoriatic arthritis of 43.7% versus 15.7%.

Eli Lilly develops medicines across diabetes, obesity, immunology, oncology, and other therapeutic areas, including Taltz and Zepbound.

The company said improvements in systemic inflammation markers, BMI, and metabolic measures were sustained or further improved through one year, with adverse events generally mild to moderate and consistent with known safety profiles.